Reimbursement ratio of neratinib/neratinib in 2025

In 2025, the reimbursement policy for neratinib/neratinib (Neratinib), an oral irreversible pan-HER receptor tyrosine kinase inhibitor, has been gradually improved in the Chinese market. According to the latest medical insurance adjustment information, neratinib has been included in the National Medical Insurance Catalog as a Class B drug, but it can only be used by patients with HER2-positive early breast cancer who meet specific clinical conditions, especially those who require intensive adjuvant therapy after completing trastuzumab-containing adjuvant therapy. Category B means that while patients enjoy medical insurance reimbursement, they still need to bear part of the expenses according to local medical insurance policies, so the actual reimbursement ratios vary in different provinces and cities.

Looking at the overall trend, the reimbursement ratio in some provinces and cities has reached around 70%. However, in economically developed areas, policy implementation is stronger and the patient out-of-pocket ratio is relatively low. Some local medical insurance policies will further adjust the reimbursement amount based on whether the patient receives treatment in a designated hospital, whether electronic filing is completed, and the treatment cycle. In addition, the combined use of special funds for female breast cancer in some regions has also further reduced the overall medication burden on patients.

The medical insurance coverage of neratinib in overseas markets also provides an important reference for domestic policies. In the United States, the drug has already been approved by the FDA for extended adjuvant treatment of HER2-positive early breast cancer; in some European countries, its cost can be partially borne by the national health system (NHS, etc.). China's medical insurance was included relatively late, but since its inclusion in the catalog, its drug accessibility has significantly improved. Especially for patients with limited economic conditions but who meet the indications, the intervention of medical insurance has far-reaching significance in prolonging survival and improving quality of life.

Reference materials:https://en.wikipedia.org/wiki/Neratinib